Skip to main content
Log in

Aliskiren

A Review of its Use in the Management of Hypertension

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Aliskiren (Tekturna®) is an orally active, nonpeptidic inhibitor of renin, the enzyme involved in the initial and rate-limiting step of the renin-angiotensin system (RAS). In the US, aliskiren is approved for the treatment of hypertension and may be used alone or in combination with other antihypertensive agents.

Monotherapy with aliskiren 150–300mg once daily was effective in lowering blood pressure (BP) and providing 24-hour BP control; it was generally well tolerated when administered for up to 1 year to patients with mild to moderate hypertension. In the short term (1–3 months), the BP-lowering effect of aliskiren 150–300mg once daily was significantly greater than that of hydrochlorothiazide (HCTZ) 12.5–25mg once daily and noninferior to, or significantly greater than, that of ramipril 5–10mg once daily. It was similar to that of valsartan 160–320mg once daily and losartan 100mg once daily, and similar to, or significantly greater than, that of irbesartan 150mg once daily. Aliskiren provided significant additional BP-lowering effects when combined with HCTZ 12.5–25 mg/day, ramipril 5–10 mg/day, amlodipine 5mg once daily or valsartan 160–320 mg/day; combination therapy was well tolerated. Long-term administration of aliskiren-based therapy was superior to HCTZ- and ramipril-based therapies in lowering BP after 6 months, and was similarly well tolerated.

The ultimate role of aliskiren will be determined by the results of target organ protection studies, which are ongoing, and a cardiovascular outcome trial, which is planned. Nonetheless, by offering a new approach to the blockade of the RAS, aliskiren provides a useful addition to the therapeutic options available to treat patients with mild to moderate hypertension.

Pharmacological Properties

Aliskiren is an orally-active, nonpeptidic, direct inhibitor of renin, the enzyme involved in the initial and rate-limiting step in the RAS cascade that results in angiotensin II production. Aliskiren reduces plasma renin activity (PRA), despite stimulating dose-dependent increases in plasma renin levels. In comparison, ACE inhibitors and angiotensin II receptor antagonists increase both PRA and renin levels; however, the clinical implications of the differences in effect on PRA are not known. Aliskiren continues to reduce PRA when combined with other antihypertensive agents that (as monotherapy) increase PRA and renin levels.

Aliskiren demonstrated dose-linear pharmacokinetics over the dose range 75–600mg in healthy volunteers. It has a low absolute bioavailability (≈2.5%); plasma concentrations of the drug are substantially reduced when aliskiren is administered with a high fat meal. Following oral administration, aliskiren undergoes minimal metabolism and is mainly eliminated as unchanged (mostly unabsorbed) compound in the faeces. The mean elimination half-life of aliskiren (≈40 hours) permits once-daily administration.

Aliskiren has a low potential for drug interactions; coadministration of aliskiren with many other commonly used antihypertensive and cardiovascular medications (e.g. amlodipine, HCTZ, ramipril, valsartan, atenolol, lovastatin and digoxin) did not result in clinically relevant drug interactions.

Therapeutic Efficacy

Short-term (8 weeks) monotherapy with recommended dosages of aliskiren 150 and 300mg once daily was consistently and, almost without exception, superior to placebo in lowering trough mean sitting diastolic blood pressure (primary efficacy variable) and trough mean sitting systolic blood pressure in patients with mild to moderate hypertension. The BP-lowering effect of aliskiren was evident after 2 weeks and near maximal after 4 weeks of treatment; it was sustained and consistent throughout the 24-hour dosing interval. Responder and BP control rates were mostly higher (relative to placebo) with aliskiren 150 mg/day and consistently higher with aliskiren 300 mg/day. There was no evidence of rebound hypertension after discontinuation of aliskiren.

Aliskiren 150–300mg once daily provided a short-term (1–3 months) BP-lowering effect that was significantly greater than that of HCTZ 12.5–25mg once daily and noninferior to, or significantly greater than, that of ramipril 5–10mg once daily. It was similar to that of valsartan 160–320mg once daily and losartan 100mg once daily, and similar to, or significantly greater than, that of irbesartan 150mg once daily. Aliskiren 150–300 mg/day provided significant additional BP-lowering effects when combined with HCTZ 12.5–25 mg/day, ramipril 5–10 mg/day, amlodipine 5 mg/day or valsartan 160–320 mg/day.

Aliskiren 150–300 mg/day was effective in the treatment of mild to moderate hypertension for up to 1 year; there was no evidence of rebound hypertension following aliskiren withdrawal. Aliskiren-based therapy (i.e. aliskiren as monotherapy or in combination with another antihypertensive agent) was superior to HCTZ-and ramipril-based therapies in lowering BP after 6 months.

Tolerability

Short-term monotherapy with aliskiren 150–300 mg/day was generally well tolerated, with an adverse event profile similar to that of placebo. Adverse events commonly associated with aliskiren monotherapy included headache, nasopharyngitis and diarrhoea. Although data indicate that diarrhoea may be more frequent with aliskiren at dosages ≥300 mg/day than with placebo, this and other gastrointestinal symptoms (which include abdominal pain, dyspepsia and gastrointestinal reflux) are typically mild and rarely result in discontinuation of treatment.

Short-term (1–3 months) monotherapy with aliskiren 150 and 300 mg/day was at least as well tolerated as that with other antihypertensive agents (HCTZ 6.25–25mg, losartan 100mg, irbesartan 150mg, valsartan 160–320mg and ramipril 5–10mg; all administered once daily). Moreover, short-term combination therapy with aliskiren 150–300 mg/day plus ramipril 5–10 mg/day resulted in a numerically lower incidence of cough and headache compared with ramipril monotherapy at the same dosages, while aliskiren 150–300 mg/day combined with amlodipine 5 mg/day resulted in a significantly lower incidence of peripheral oedema compared with amlodipine monotherapy at double the dosage.

Long-term administration of aliskiren-based therapy was well tolerated for up to 1 year. Combining aliskiren with HCTZ was as well tolerated as ramipril combined with HCTZ, while aliskiren combined with amlodipine was as well tolerated as HCTZ combined with amlodipine, in terms of the frequency of adverse events after 6 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II
Table III
Table V
Table IV
Fig. 3
Table VI

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drug 2003; 3(6): 389–94

    Article  CAS  Google Scholar 

  2. O’Brien E. Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension. Expert Opin Investig Drugs 2006 Oct; 15(10): 1269–77

    Article  PubMed  Google Scholar 

  3. Azizi M. Renin inhibition. Curr Opin Nephrol Hypertens 2006 Sep; 15(5): 505–10

    Article  PubMed  CAS  Google Scholar 

  4. Muller DM, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006; 1: 221–8

    Article  PubMed  Google Scholar 

  5. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004 Jun 1; 109(21): 2492–9

    Article  PubMed  Google Scholar 

  6. Van Tasseil BW, Mutiger MA. Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother 2007 Mar; 41(3): 456–64

    Article  Google Scholar 

  7. Alderman MH, Ooi WL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997 Jan; 10(1): 1–8

    Article  PubMed  CAS  Google Scholar 

  8. Kehoe B, Keeton GR, Hill C. Elevated plasma renin activity associated with renal dysfunction. Nephron 1986; 44: 51–7

    Article  PubMed  CAS  Google Scholar 

  9. Malmqvist K, Ohman KP, Lind L. Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 2002; 252: 430–9

    Article  PubMed  CAS  Google Scholar 

  10. Wood JM, Maibaum J. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003 Sep 5; 308(4): 698–705

    Article  PubMed  CAS  Google Scholar 

  11. Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006 Feb; 24(2): 243–56

    Article  PubMed  CAS  Google Scholar 

  12. Cogolludo A, Perez-Vizcaino F, Tamargo J. New insights in the pharmacological therapy of arterial hypertension. Curr Opin Nephrol Hypertens 2005; 14(5): 423–7

    Article  PubMed  CAS  Google Scholar 

  13. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006 Oct 21; 368: 1449–56

    Article  PubMed  CAS  Google Scholar 

  14. Schmieder RE. Aliskiren: a clinical profile. J Renin Angiotensin Aldosterone Syst 2006 Jan; 7(2): S16–20

    Article  CAS  Google Scholar 

  15. Luft FC. Achieving the goal of optimised renin system suppression: preclinical experience with a direct renin inhibitor. J Renin Angiotensin Aldosterone Syst 2006 Jan; 7(2): S12–5

    Article  CAS  Google Scholar 

  16. Brown MJ. Direct renin inhibition a new way of targeting the renin system. J Renin Angiotensin Aldosterone Syst 2006 Jan; 7(2): S8–S11

    Article  Google Scholar 

  17. Kjeldsen SE. Direct renin inhibition with focus on aliskiren and cardiovascular outcome studies [online]. Available from URL: http://www.touchbriefings.com/pdf/2475/Kjedsen.pdf [Accessed 2007 Mar 20]

  18. Gradman AH, Traub D. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. Rev Cardiovasc Med 2007; 8 Suppl. 2: S22–30

    PubMed  Google Scholar 

  19. Tekturna® (aliskiren tablets): US prescribing information. East Hanover (NJ), Novartis Pharmaceuticals Corporation: 2007

  20. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002 Jan; 39(1): E1–8

    Article  PubMed  CAS  Google Scholar 

  21. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004 Dec; 15(12): 3126–33

    Article  PubMed  Google Scholar 

  22. O’Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276–84

    Article  PubMed  Google Scholar 

  23. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003 Dec; 42(6): 1137–43

    Article  PubMed  CAS  Google Scholar 

  24. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007 Mar 20; 49(11): 1157–63

    Article  PubMed  CAS  Google Scholar 

  25. Calhoun D, Chrysant S, Villamil A, et al. The novel oral renin inhibitor aliskiren decreases plasma renin activity (PRA) and neutralizes hydrochlorothiazide-induced RAAS activation in hypertensive patients [abstract no. P-168]. J Clin Hypertens 2006; 8 (5 Suppl. A): A77. Plus poster presented at the 21st Annual Scientific Meeting of the American Society of Hypertension; 2006 May 16–20; New York (NY)

    Google Scholar 

  26. Gradman AH, Flack JM, Arora V, et al. Suppression of the renin system by the novel orally effective direct renin inhibitor aliskiren: a pooled analysis of 1612 patients with hypertension [abstract no. 3620]. Circulation 2006 Oct 31; 114 Suppl. 18: 11–773. Plus poster C159 presented at the American Heart Association Scientific Sessions; 2006 Nov 12–15; Chicago (IL)

    Google Scholar 

  27. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005 Mar 1; 111(8): 1012–8

    Article  PubMed  CAS  Google Scholar 

  28. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217–26

    Article  PubMed  CAS  Google Scholar 

  29. Uresin Y, Taylor A, Kilo C, et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension [abstract no. P4.269]. J Hypertens 2006 Jun; 24 Suppl. 4: 82

    Google Scholar 

  30. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised double-blind trial. Lancet 2007 Jul 21; 370: 221–9

    Article  PubMed  CAS  Google Scholar 

  31. Andersen K, Weinberger MH, Egan B, et al. Aliskiren-based therapy lowers blood pressure more effectively than ramipril-based therapy in patients with hypertension: a 6-month, randomized, double blind trial [abstract no. 1014-173]. J Am Coll Cardiol 2007 Mar 6; 49 (9 Suppl. A): 371. Plus poster presented at the 56th Annual Scientific Session of the American College of Cardiology; 2007 Mar 24–27; New Orleans (LA)

    Google Scholar 

  32. Weinberger MH, Andersen K, Constance CM, et al. Aliskiren-based therapy provides long-term suppression of plasma renin activity that persists after treatment withdrawal in patients with hypertension [abstract no. 1020-168]. J Am Coll Cardiol 2007 Mar 6; 49 (9 Suppl. A): 390–391. Plus poster presented at the 56th Annual Scientific Session of the American College of Cardiology; 2007 Mar 24–27; New Orleans (LA)

    Google Scholar 

  33. Vaidyanathan S, Limoges D, Yeh C, et al. Aliskiren, an orally effective renin inhibitor shows dose linear pharmacokinetics in healthy volunteers [abstract no. PIII-23]. Clin Pharmacol Ther 2006 Feb; 79(2): P64

    Article  Google Scholar 

  34. Vaidyanathan S, Jermany J, Yeh CM, et al. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects [abstract no. P-191]. Am J Hypertens 2005 May; 18(5 Pt 2): 75A

    Article  Google Scholar 

  35. Data on file, Novartis Pharmaceuticals Corporation, 2007

  36. Waldmeier FJ, Glaenzel U, Wirz B, et al. Absorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007 Aug; 35(8): 1418–28. Epub 2007 May 17

    Article  PubMed  CAS  Google Scholar 

  37. Vaidyanathan S, Bigler H, Yeh C-M, et al. Safety, tolerability and pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007; 46(8): 661–75

    Article  PubMed  CAS  Google Scholar 

  38. Zhao C, Vaidyanathan S, Yeh CM, et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006; 45(11): 1125–34

    Article  PubMed  CAS  Google Scholar 

  39. Vaidyanathan S, Reynolds C, Yeh CM, et al. Pharmacokinetics, safety, and tolerability of the novel oral direct Renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007 Apr; 47(4): 453–60

    Article  PubMed  CAS  Google Scholar 

  40. Vaidyanathan S, Warren V, Yeh C, et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007 Feb; 47(2): 192–200

    Article  PubMed  CAS  Google Scholar 

  41. Dieterich H, Kemp C, Vaidyanathan S, et al. Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther 2006 Feb 1; 79(2): 64

    Article  Google Scholar 

  42. Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Prac 2006 Nov; 60(11): 1343–56

    Article  CAS  Google Scholar 

  43. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004 Oct; 58(4): 433–6

    Article  PubMed  Google Scholar 

  44. Dieterle W, Corynen S, Vaidyanathan S, et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005 Nov; 43(11): 527–35

    PubMed  CAS  Google Scholar 

  45. Dieterich HA, Yeh C, Howard D, et al. Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: a study in healthy volunteers [abstract no. PIII-78]. Clin Pharmacol Ther 2007 Mar; 81 Suppl. 1: S110

    Google Scholar 

  46. Reynolds C, Vaidyanathan S, Dieterich HA, et al. Assessment of pharmacokinetic interaction between aliskiren, a novel direct renin inhibitor, and metformin in healthy volunteers [abstract no. PIII-77]. Clin Pharmacol Ther 2007 Mar; 81 Suppl. 1: S110

    Google Scholar 

  47. Kushiro T, Itakura H, Abo Y, et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006 Dec; 29(12): 997–1005

    Article  PubMed  CAS  Google Scholar 

  48. Kushiro T, Itakura H, Abo Y, et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. J Hypertens 2006 Dec; 24 Suppl. 6: 99–100. Plus poster PM1-01-02 presented at the 21st Scientific Meeting of the International Society of Hypertension; 2006 Oct 15–19; Fukuoka

    Google Scholar 

  49. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11–20

    Article  PubMed  CAS  Google Scholar 

  50. Mitchell J, Oh B, Herron J, et al. Once-daily aliskiren provides effective, smooth 24-hour blood pressure control in patients with hypertension. J Clin Hypertens 2006; 8 (5 Suppl. A): A93. Plus poster presented at the 21st Annual Scientific Meeting of the American Society of Hypertension; 2006 May 16–20; New York (NY)

    Google Scholar 

  51. Herron J, Mitchell J, Oh B, et al. The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal [abstract no. P-193]. J Clin Hypertens 2006 May; 8 Suppl. A: A86–7

    Google Scholar 

  52. Yarrows SA, Oparil S, Patel S, et al. Aliskiren in combination with valsartan provides superior 24-hour ambulatory blood pressure reductions compard with either agent alone in patients with hypertension [abstract no. P-452]. J Clin Hypertens 2007 May; 9 (5 Suppl. A): 188–9

    Google Scholar 

  53. Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007 May; 49(5): 1047–55

    Article  PubMed  CAS  Google Scholar 

  54. Munger MA, Drummond W, Essop MR, et al. Aliskiren as addon to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose [abstract no. P784]. Eur Heart J 2006 Sep; 27 (Abstr. Suppl.): 117

    Google Scholar 

  55. Schmieder RE, Philipp T, Guerediaga J, et al. Aliskiren-based therapy lowers blood presure more effectively than hydrochlorothiazide-based therapy in patients with hypertension [abstract no. P-436]. J Clin Hypertens 2007 May; 9 (5 Suppl. A): 182

    Google Scholar 

  56. Sica D, Gradman A, Lederballe O, et al. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension [abstract no. P797]. Eur Heart J 2006 Sep; 27 (Abstr. Suppl.): 121. Plus poster presented at the World Congress of Cardiology; 2006 Sep 2–6; Barcelona

    Google Scholar 

  57. Keefe DL, Andersen K, Weinberger MH, et al. Blood pressure lowering effects persist following the last dose of long-term therapy with aliskiren, an oral direct renin inhibitor [abstract no. 1014-204]. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 372. Plus poster presented at the 56th Annual Scientific Session of the American College of Cardiology; 2007 Mar 24–27; New Orleans (LA)

    Google Scholar 

  58. Novartis Pharmaceuticals Corporation. New drug application (NDA) for Rasilez® (aliskiren), an innovative oral renin inhibitor to treat high blood pressure, accepted for review by the US FDA [media release]. 2006

  59. Novartis Pharmaceuticals Corporation. Novartis seeks European approval for Rasilez® to become the first in a new class of medicines to help patients with high blood pressure [media release]. 2006

  60. Gradman AH, Kolloch RE, Meyers M, et al. Aliskiren in combination with hydrochlorothiazide is effective and well tolerated during long-term treatment of hypertension [abstract no. P-384]. J Clin Hypertens 2007 May; 9 (5 Suppl. A): 160

    Google Scholar 

  61. Oh BH, Chung J, Khan M, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy, and placebo-like tolerability in patients with hypertension [abstract no. 1027]. J Am Coll Cardiol 2006 Feb 21; 47 (4 Suppl. A): 370–371. Plus poster presented at the American College of Cardiology 55th Annual Scientific Sessions; 2006 Mar 11–14; Atlanta (GA)

    Google Scholar 

  62. Tschoepe D, Taylor A, Kilo C, et al. Aliskiren, alone and in combination with ramipril, significantly lowers blood pressure and plasma renin activity in patients with diabetes and hypertension, regardless of the degree of glycaemic control [abstract no. 0217]. Diabetologia 2006 Sep; 49 Suppl. 1: 136. Plus oral presentation at the 16th European Meeting on Hypertension; 2006 Jun 12–16; Madrid

    Google Scholar 

  63. Taylor A, Tschope D, Kilo C, et al. Adding aliskiren to ramipril improves 24-hour blood pressure control compared to ramipril alone in patients with diabetes and hypertension [abstract no. P4.268]. J Hypertens 2006 Jun; 24 Suppl. 4: 81–2

    Google Scholar 

  64. Weir MR, Bush C, Zhang J, et al. Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis [abstract no. 1796]. Eur Heart J 2006 Sep; 27 (Abstr. Suppl.): 299. Plus oral presentation at the World Congress of Cardiology; 2006 Sep 2–299. Plus oral presentation at the World Congress of Cardiology; 2006; Barcelona

    Google Scholar 

  65. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15; 365(9455): 217–23

    PubMed  Google Scholar 

  66. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 Nov; 21(11): 1983–92

    Article  PubMed  Google Scholar 

  67. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21 (6): 1011–53

  68. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289(19): 2560–72

    Article  PubMed  CAS  Google Scholar 

  69. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004 Mar; 18(3): 139–85

    Article  PubMed  CAS  Google Scholar 

  70. Weir MR. Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. J Clin Hypertens 2006 Feb; 8(2): 99–105

    Article  CAS  Google Scholar 

  71. Neal B, MacMahon S, Chapman N, et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000 Dec 9; 356(9246): 1955–64

    CAS  Google Scholar 

  72. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada and the United States. Hypertension 2004 Jan; 43(1): 10–7

    Article  PubMed  CAS  Google Scholar 

  73. WHO. World Health Report 2002: reducing risk, promoting healthy life. Geneva, Switzerland: World Health Organiztion, 2002

  74. Alexander LM. Desirable therapeutic characteristics of an optimal antihypertensive agent. Drugs 2006; 66(9): 1239–52

    Article  CAS  Google Scholar 

  75. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005 Apr; 23(1): S9–17

    Article  PubMed  CAS  Google Scholar 

  76. Drincic V, Koshy S, Bakris G. Angiotensin receptor blocker use for hypertension treatment in the elderly. Annals of Long-Term Care 1999; 7(8): 305–8

    Google Scholar 

  77. EMEA Press Release. Meeting highlights from the Committee for Medicinal Products for Human Use, 18–21 June 2007 [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Jul 5]

  78. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ [Accessed 2007 Feb 13]

  79. Novartis Pharmaceuticals USA. Novartis announces three-month extension of US regulatory review period for Tekturna [media release]. 2006

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to James E. Frampton.

Additional information

Various sections of the manuscript reviewed by: M. Azizi, Faculté de Médecin, Université Paris Descartes, Paris, France; A. Cogolludo, Department of Pharmacology, Universidad Complutense, Madrid, Spain; J.A. Jessup, Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA; M.A. Munger, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA; D.A. Sica, Department of Medicine, Virginia Commonwealth University Health System, Richmond, Virginia, USA; J.A. Staessen, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium; Y. Uresin, Department of Pharmacology and Clinical Pharmacology, Instanbul University, Capa, Turkey.

Data Selection

Sources: Medical literature published in any language since 1980 on ‘aliskiren’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Wolters Kluwer Health | Adis). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘aliskiren’. Searches were last updated 2 July 2007.

Selection: Studies in patients with mild to moderate hypertension who received aliskiren. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Aliskiren, renin inhibitors, renin-angiotensin system, hypertension, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frampton, J.E., Curran, M.P. Aliskiren. Drugs 67, 1767–1792 (2007). https://doi.org/10.2165/00003495-200767120-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767120-00008

Keywords

Navigation